Prof Salvatore Siena; Università degli Studi di Milano, Milan, Italy; [email protected]A Phase 2, Multicenter, Open-Label Study of Trastuzumab Deruxtecan (T-DXd; DS-8201) in Patients With HER2-Expressing Metastatic Colorectal Cancer: DESTINY-CRC01 Salvatore Siena, Maria Di Bartolomeo, Kanwal Raghav, Toshiki Masuishi, Fotios Loupakis, Hisato Kawakami, Kensei Yamaguchi, Tomohiro Nishina, Marwan Fakih, Elena Elez, Javier Rodriguez, Fortunato Ciardiello, Kapil Saxena, Eriko Yamamoto, Emarjola Bako, Yasuyuki Okuda, Javad Shahidi, Axel Grothey, Takayuki Yoshino On behalf of the DESTINY-CRC01 investigators
16
Embed
A Phase 2, Multicenter, Open-Label Study of Trastuzumab ...
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Prof Salvatore Siena; Università degli Studi di Milano, Milan, Italy; [email protected]
A Phase 2, Multicenter, Open-Label Study of Trastuzumab Deruxtecan (T-DXd; DS-8201) in Patients With HER2-Expressing Metastatic Colorectal Cancer:
DESTINY-CRC01
Salvatore Siena, Maria Di Bartolomeo, Kanwal Raghav, Toshiki Masuishi, Fotios Loupakis, Hisato Kawakami, Kensei Yamaguchi, Tomohiro Nishina, Marwan Fakih, Elena Elez,
Javier Rodriguez, Fortunato Ciardiello, Kapil Saxena, Eriko Yamamoto, Emarjola Bako, Yasuyuki Okuda, Javad Shahidi, Axel Grothey, Takayuki Yoshino
On behalf of the DESTINY-CRC01 investigators
Prof Salvatore Siena; Università degli Studi di Milano, Milan, Italy; [email protected]
T-DXd is a Novel ADC Designed to Deliver an Antitumor Effect
2
The clinical relevance of these features is under investigation.ADC, antibody-drug conjugate.1. Nakada T, et al. Chem Pharm Bull (Tokyo). 2019;67(3):173-185. 2. Ogitani Y, et al. Clin Cancer Res. 2016;22(20):5097-5108. 3. Trail PA, et al. Pharmacol Ther. 2018;181:126-142. 4. Ogitani Y, et al. Cancer Sci. 2016;107(7):1039-1046.
T-DXd is an ADC with 3 components:• A humanized anti-HER2 IgG1 mAb with the same amino acid sequence as trastuzumab• A topoisomerase I inhibitor payload, an exatecan derivative• A tetrapeptide-based cleavable linker
Payload mechanism of action: topoisomerase I inhibitor
High potency of payload
High drug to antibody ratio ≈ 8
Payload with short systemic half-life
Stable linker-payload
Tumor-selective cleavable linker
Membrane-permeable payload
Prof Salvatore Siena; Università degli Studi di Milano, Milan, Italy; [email protected]
DESTINY-CRC01 Study Design
3
Primary endpoint• Confirmed ORR by independent central
review (ICR) in Cohort A
Cohort A (n = 53)HER2 Positive (IHC 3+ or IHC 2+/ISH+)
Cohort B (n = 7) HER2 IHC 2+/ISH−
Cohort C (n = 18)HER2 IHC 1+
Patients• Unresectable and/or metastatic CRC• HER2 expressing (central confirmation)• RAS/BRAF wild type• ≥2 prior regimens• Prior anti-HER2 treatment was allowed• Excluded patients with a history of or
current/suspected interstitial lung disease
Data cutoff: August 9, 2019• 38.5% (30/78) remained on treatment• 61.5% discontinued, primarily for progressive
disease (41.0%) and clinical progression (9.0%)
An open-label, multicenter, phase 2 study (NCT03384940)
T-DXd 6.4 mg/kg q3w
A futility monitoring was done after ≥20 patients in Cohort A had 12 weeks of follow-up to inform opening of Cohorts B and C
Prof Salvatore Siena; Università degli Studi di Milano, Milan, Italy; [email protected]
a Left: rectum, sigmoidal, descending; Right: cecum, ascending, transverse. b By local assessment. c 1 patient had an NRAS mutation. d By central assessment. Sums may not total 100% due to rounding.
Prof Salvatore Siena; Università degli Studi di Milano, Milan, Italy; [email protected]
DESTINY-CRC01
5
Prior Treatments
• Prior anti-HER2 agents in Cohort A included pertuzumab (24.5%), trastuzumab (22.6%), T-DM1 (5.7%), lapatinib (5.7%), and tucatinib (1.9%)
Duration of response, median Not reached (95% CI, 4.2 months-NE)
a Patients were missing postbaseline scans.Median study duration, 5.0 months (range, 0.6-10.5 months). There were no confirmed responses by ICR in Cohort B or C.
Prof Salvatore Siena; Università degli Studi di Milano, Milan, Italy; [email protected]
DESTINY-CRC01 Cohort A
-100
-80
-60
-40
-20
0
20
40
7
Best Change in Tumor Size
HER2+ Cohort A (N = 53)
Best
% C
hang
e Fr
om B
asel
ine
in th
e S
um
of D
iam
eter
s of M
easu
rabl
e Tu
mor
s
*
IHC3+IHC2+/ISH+Prior anti-HER2 treatmentHER2 IHC2+/ISH+ with an NRAS mutation*
Prof Salvatore Siena; Università degli Studi di Milano, Milan, Italy; [email protected]
DESTINY-CRC01 Cohort A
8
Tumor Shrinkage Over Time
Baseline 2 8 10
100%
Cha
nge
in S
um o
f Dia
met
ers f
rom
Base
line
HER2+ Cohort A (N = 53)
80
60
40
20
0
-20
-40
-60
-80
-100
Time (Months) from First Dose of Study Drug4 6
Prof Salvatore Siena; Università degli Studi di Milano, Milan, Italy; [email protected]
DESTINY-CRC01 Cohort A
9
Response by SubgroupORR, % [95% CI]
HER2+ Cohort A N = 53 45.3 [31.6-59.6]
Age < 65 y (n = 35) 42.9 [26.3-60.6]≥ 65 y (n = 18) 50.0 [26.0-74.0]
Median follow-up for OS was 5.4 month (range, 1.2-11.8 months).
Prof Salvatore Siena; Università degli Studi di Milano, Milan, Italy; [email protected]
DESTINY-CRC01
11
Overall Safety Summary
• Median treatment duration– HER2+ patients, 4.8 months (range, 1-11)– All patients, 3.5 months (range, 1-11)
• Causes of death related to study drug according to investigator assessment (n = 2) included pneumonitis (n = 1) and ILD (n = 1), both in HER2+ Cohort A
TEAE, treatment-emergent adverse event. a Relationship to study drug was determined by the treating investigator. b Each of the following TEAEs was associated with a fatal outcome: sepsis, meningism, disease progression (n = 2), general physical health deterioration (all unrelated to T-DXd), interstitial lung disease, and pneumonitis (both related to T-DXd).
Type of Adverse Event, n (%)aHER2+ Cohort A
(n = 53)All Patients
(N = 78)Any TEAE
Drug-related53 (100)51 (96.2)
78 (100)73 (93.6)
TEAE grade ≥3Drug-related
32 (60.4)27 (50.9)
48 (61.5)38 (48.7)
Serious TEAEDrug-related
18 (34.0)12 (22.6)
26 (33.3)14 (17.9)
Dose adjustments
TEAE associated with discontinuationDrug-related
5 (9.4)2 (3.8)
7 (9.0)2 (2.6)
TEAE associated with dose reductionDrug-related
11 (20.8)10 (18.9)
15 (19.2)14 (17.9)
TEAE associated with dose interruptionDrug-related
20 (37.7)15 (28.3)
27 (34.6)19 (24.4)
Death
TEAE associated with deathb
Drug-related5 (9.4)2 (3.8)
7 (9.0)2 (2.6)
Prof Salvatore Siena; Università degli Studi di Milano, Milan, Italy; [email protected]
DESTINY-CRC01
12
Treatment-Emergent Adverse Events in >15% of Patients
Patients (%)0 10 20 30 40 50 60 70
WBC count decreased
Hypokalemia
Alopecia
Diarrhea
Vomiting
Platelet count decreased
Decreased appetite
Fatigue
Neutrophil count decreased
Anemia
Nausea
Grade 1 & 2Grade ≥3
All Patients (N = 78)a
a Grade ≥3 neutrophil count decreased, 25.6%; no patients had febrile neutropenia.
Prof Salvatore Siena; Università degli Studi di Milano, Milan, Italy; [email protected]
DESTINY-CRC01
13
AEs of Special Interest: Interstitial Lung Disease
Drug related; ILD was determined by an Independent ILD Adjudication Committee based on 44 preferred terms.One additional grade 5 ILD case in Cohort B was reported after the data cutoff. This case was adjudicated after data cutoff as drug-related ILD.
Among the 5 total events:• Median time to investigator-reported onset was 80 days (range, 22-132)• 5 of 5 patients with grade ≥ 2 ILD received corticosteroids• 2 patients recovered, 1 did not recover (later died due to disease progression), and 2 died• In the 2 fatal cases, onset was from 40-126 days, both received steroids as part of treatment, and
death occurred 6-18 days after diagnosis
Protocol recommendations: Monitor for symptoms. Hold T-DXd and start steroids as soon as ILD is suspected
Prof Salvatore Siena; Università degli Studi di Milano, Milan, Italy; [email protected]
DESTINY-CRC01
14
Conclusions• T-DXd 6.4 mg/kg q3w demonstrated promising and durable activity in patients with HER2-positive
(IHC 3+, IHC 2+/ISH+) metastatic CRC refractory to standard therapies• ORR, 45.3%; median DOR not reached• Consistent responses were seen across subgroups, including prior anti-HER2 therapy• Median PFS, 6.9 months
• No responses were observed in the 2 cohorts of metastatic CRC with low HER2 expression (IHC 2+/1+)
• The safety profile is consistent with what has been previously reported1-5
• Low grade gastrointestinal and hematologic AEs were most common• ILD (6.4% of patients; 2.6% grade 5) is an important risk and requires careful monitoring and prompt
intervention
• These data demonstrate the potential of T-DXd as a treatment option for patients with advanced HER2-positive CRC
1. Tsurutani J, et al. Cancer Discov. 2020; Mar [epub ahead of print]; 2. Tamura K et al. Lancet Oncol. 2019;20(6):816-826; 3. Modi S, et al. N Engl J Med. 2020;382(7):610-621; 4. Modi S, et al. J Clin Oncol. Feb [epub ahead of print]; 5. Shitara K, et al. Lancet Oncol. 2019;20(6):827-836.
Prof Salvatore Siena; Università degli Studi di Milano, Milan, Italy; [email protected]
The patients and their families
The study site stafffor their participation for their contributions
We would like to thank:
&
This study was sponsored and designed by:Daiichi SankyoCollaborator:AstraZeneca
Medical writing support was provided by:John Togneri, PhD (Articulate Science LLC) and was funded by Daiichi Sankyo, Inc.
15
Prof Salvatore Siena; Università degli Studi di Milano, Milan, Italy; [email protected]
DESTINY-CRC01 Cohort A
16
Investigators
ItalyMaria Di BartolomeoFotios LoupakisSalvatore SienaFortunato Ciardiello